Cyramza market seen rising to $1.79 million by 2030

The market for Cyramza (ramucirumab) is projected to grow from $1.31 million in 2025 to $1.79 million by 2030, driven by cancer prevalence, aging populations and broader use in oncology. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Cyramza is used in cancer treatment, so market growth tracks demand for advanced oncology drugs. - The report points to expanding use in hospital oncology settings, which can affect treatment access and purchasing patterns. - The forecast suggests stronger adoption of anti-angiogenic and combination therapies through 2030.

What happened: - The Business Research Company published a new global market report on Cyramza (ramucirumab) on November 2, 2026. - The report estimates the market will rise from $1.31 million in 2025 to $1.4 million in 2026. - The report projects the market will reach $1.79 million by 2030. - The report says the market is growing at a 6.7% CAGR from 2025 to 2026 and a 6.3% CAGR through 2030. - The report covers market segments, regional developments and leading competitors. - The report includes a free sample, available as the sample request. - The company also offers the full market report.

The details: - Cyramza is a monoclonal antibody used in oncology. - The drug targets vascular endothelial growth factor receptor 2, or VEGFR-2. - That mechanism inhibits blood vessel formation that tumors need to grow. - The report identifies use in gastric, colorectal and lung cancer, among other cancers. - Regulatory approvals for gastric and colorectal cancers are one of the growth drivers cited in the report. - The rising global cancer burden is another growth driver. - Successful clinical outcomes for VEGFR inhibitors are also listed as a driver. - Limited treatment options for late-stage cancers are supporting demand. - The report also points to increasing incidence of solid tumors, expansion into new cancer indications and rising healthcare spending on oncology. - Improved diagnostic rates are expected to help support growth. - The report highlights growth in personalized cancer treatment as a tailwind for Cyramza. - The report says 16 new personalized therapies for rare diseases were approved by the FDA in 2023, up from six in 2022. - The report says North America held the largest share of the Cyramza market in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period. - The analysis also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The market outlook reflects a broader shift toward targeted cancer therapies rather than one-size-fits-all treatment. - The emphasis on aging populations and cancer incidence suggests demand is being driven by long-term demographic pressure, not just near-term product cycles. - The regional split implies mature markets still dominate revenue, while faster growth is shifting toward regions with expanding oncology access.

What's next: - The report expects continued adoption of combination treatments with chemotherapy. - The report expects broader use across multiple cancer types. - The report expects higher demand for advanced-stage cancer therapies. - The company says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.